Chronic Kidney Failure
Conditions
Brief summary
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of time.
Detailed description
High levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (PTH), bone disease, formation of calcium deposits in the body, and blood-vessel disease). This study is an open-label, multi-centre, single-group, 24-week study of fermagatebonate. Subjects participating in this study are those who took at least one dose of double-blind study medication in the IH 001 study and either completed study IH 001 or were withdrawn due to reasons other than an adverse event (AE) considered related to study treatment.
Interventions
DRUGFermagate
Film coated tablet 500mg
Sponsors
Ineos Healthcare Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment 2. Male or female subjects on active haemodialysis, aged 18 years or over 3. Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication; 4. Willing to avoid any intentional changes in diet such as fasting, dieting or overeating; 5. Willing to maintain their usual type and dose of Vitamin D supplementation.
Exclusion criteria
1. Participation in any other clinical trial using an investigational product or device within the previous 4 months; 2. A significant history of alcohol, drug or solvent abuse in the opinion of the investigator; 3. Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn; 4. Clinically significant laboratory findings (for this subject population) in the opinion of the investigator. 5. Any malignancy with the exception of basal cell carcinoma; 6. A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction; 7. A significant illness in the 4 weeks before screening; 8. Taking medication for seizures; 9. A history of haemochromatosis; 10. A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation); 11. A history of dysphagia or swallowing disorders; 12. Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device; 13. Current haemoglobin concentration of \< 10.00 g/dL; 14. Allergy to the IMP or its constituents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of AEs and other safety parameters | 88 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of serum phosphate concentrations | 88 weeks |
Countries
United Kingdom, United States
Outcome results
None listed